On October 1, 2022 Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, reported that it has appointed Jason Sager, MD, as Chief Medical Officer (CMO) (Press release, Angiex, OCT 1, 2022, View Source [SID1234621831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following a 12-year career as a practicing pediatric oncologist, Dr. Sager gained extensive oncology drug development experience at Genentech, Novartis, Sanofi and Ikena Oncology where he led the early clinical development of many important therapeutics. His résumé includes 14 INDs. Over the past 18 months, he led the design of the clinical program for Angiex’s lead drug, AGX101.

Angiex CEO, Marty J. Duvall said, "The addition of Jason to our executive team is a critical step in the growth of our company. His extensive know-how and drug development network will help accelerate our company forward."

"I am highly motivated to join Angiex. The company has a deep scientific foundation in angiogenesis, vascular biology, and antibody-drug conjugate chemistry. I am driven to translate that into a meaningful benefit for cancer patients," said Dr. Sager.

Iain Dukes, executive chairman of Angiex and venture partner of Orbimed Advisors, said, "Adding Jason to the executive team marks another important milestone in the building of Angiex. Angiex’s ND-ADC technology holds great promise for the treatment of solid cancers and deserves a world-class team to drive it forward."